Tuesday, 10 July 2012

Propylthiouracil


Class: Antithyroid Agents
ATC Class: H03BA02
VA Class: HS852
CAS Number: 51-52-5



  • Severe liver injury and acute liver failure, in some cases requiring liver transplantation or resulting in death, reported in adult and pediatric patients.109 (See Hepatotoxicity under Cautions.)




  • Reserve propylthiouracil for patients who cannot tolerate methimazole and for whom radioactive iodine therapy or surgery are not appropriate for the management of hyperthyroidism.109 (See Hyperthyroidism under Uses.)




  • Propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy because of the risk of fetal abnormalities associated with methimazole.109 (See Fetal/Neonatal Morbidity and also see Pregnancy under Cautions.)



REMS:


FDA approved a REMS for propylthiouracil (ptu) to ensure that the benefits of a drug outweigh the risks. However, FDA later rescinded REMS requirements. See the FDA REMS page () or the ASHP REMS Resource Center ().



Introduction

Antithyroid agent;109 b thiourea-derivative.b


Uses for Propylthiouracil


Hyperthyroidism


Used in patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option.109


Amelioration of symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole.109


Propylthiouracil is associated with a higher risk for clinically serious or fatal liver injury compared with methimazole in adult and pediatric patients; therefore, when initiating hyperthyroid treatment, reserve propylthiouracil for patients who cannot tolerate methimazole and for whom radioactive iodine therapy or surgery are not appropriate for the management of hyperthyroidism.100 112 100 103 107 109 112 (See Boxed Warning and also see Hepatotoxicity under Cautions.)


Not recommended for use in pediatric patients except in rare instances in which methimazole is not well tolerated and surgery or radioactive iodine therapy are not appropriate therapies.100 103 106 109 112 (See Pediatric Use under Cautions.)


May be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy because of the risk of fetal abnormalities associated with methimazole.100 103 107 108 109 112 For second and third trimesters, may be preferable to switch from propylthiouracil to methimazole because of the risk of maternal adverse effects associated with propylthiouracil (e.g., hepatotoxicity).109 (See Fetal/Neonatal Morbidity and also see Pregnancy under Cautions.)


Therapy with thioamide antithyroid agents maintains patient in euthyroid state for a period of several (generally 1–2) years until spontaneous remission occurs;b c however, spontaneous remission does not occur in all patients, and most eventually require ablative therapy (i.e., surgery, radioactive iodine).b Because thioamide antithyroid agents do not affect underlying cause of hyperthyroidism, generally avoid long-term use; minimum duration of therapy necessary before assessing whether spontaneous remission has occurred not clearly established.b


Therapy with propylthiouracil returns hyperthyroid patient to a normal metabolic state prior to thyroidectomy and controls the thyrotoxic crisis that may accompany thyroidectomy.b


Therapy with propylthiouracil controls the symptoms of hyperthyroidism before and during radioactive iodine therapy until the ablative effects of iodine occur.b However, pretreatment with thioamides may lower the cure rate and increase the need for subsequent doses of radioactive iodine.c


Thyrotoxic Crisis


May be used for management of thyrotoxic crisis;103 109 b c preferred over methimazole due to more rapid onset of effect (i.e., by inhibiting peripheral deiodination of thyroxine [T4] to triiodothyronine [T3], a dominant source of the hormone).103 c d Usually initiated before iodide (e.g., potassium iodide, strong iodine solution) therapy.b c d


Alcoholic Liver Disease


Has been studied in patients with alcoholic liver disease†.116


No substantial benefit has been demonstrated on any clinically important outcomes of alcoholic liver disease (e.g., all-cause mortality, liver-related mortality, complications associated with the liver disease, liver histology); currently available evidence does not support its use outside of randomized clinical studies.116


Propylthiouracil Dosage and Administration


General


Concomitant Therapy



  • May use a β-adrenergic blocking agent (e.g., propranolol) concomitantly to manage peripheral signs and symptoms of hyperthyroidism, particularly cardiovascular effects (e.g., tachycardia).b c



REMS Program



  • FDA has approved a Risk Evaluation and Mitigation Strategy (REMS) for propylthiouracil.112 114




  • The program consists of a medication guide that must be dispensed with every propylthiouracil prescription.112 113 114




  • The goal of the program is to inform patients about the serious risks (e.g., hepatotoxicity) associated with the use of propylthiouracil (see Cautions).114



Administration


Administer orally.109 b c May administer rectally† as extemporaneously prepared suppositories or enemas.c d o


Oral Administration


Administer total daily dosage orally in 3 equally divided doses at approximately 8-hour intervals.109 b c More frequent administration (e.g., at 4- or 6-hour intervals) may be necessary in some cases.b c


Dosage


Pediatric Patients


Hyperthyroidism

Oral

Generally not recommended for use in pediatric patients except in rare instances in which alternative therapies are not appropriate options.109 (See Pediatric Use under Cautions.) Although studies evaluating appropriate dosage regimens not conducted in pediatric population, manufacturer states that general practice would suggest initiation of therapy in children ≥6 years of age at 50 mg daily with careful upward titration based on clinical response and evaluation of TSH and free T4 concentrations.109


Severe liver injury reported with dosages as low as 50 mg daily, but most cases were associated with dosages of ≥300 mg daily.109 (See Hepatotoxicity under Cautions.)


Adults


Hyperthyroidism

Graves’ Disease with Hyperthyroidism or Toxic Multinodular Goiter

Oral

Initially, 300 mg daily.109 For patients with severe hyperthyroidism and/or very large goiters, initial dosage may be increased to 400 mg daily;109 occasionally, an initial dosage of 600–900 mg daily may be required.109


Continue therapy at initial dosage for about 4–8 weeks until symptoms resolve and euthyroidism is achieved.b c d j Then, gradually taper to a dosage that maintains euthyroidism.c d j


Usual maintenance dosage: Manufacturer recommends 100–150 mg daily.109


Most data support duration of 12–18 months.c l


Preparation for Thyroidectomy

Oral

Initially, 300 mg daily.109 For patients with severe hyperthyroidism and/or very large goiters, initial dosage may be increased to 400 mg daily;109 occasionally, an initial dosage of 600–900 mg daily may be required.109


Some clinicians recommend continuing therapy at initial dosage for about 6–8 weeks until euthyroidism is achieved; then add iodide therapy for 10–14 days (to decrease vascularity of thyroid gland) before surgery.j


Preparation for Radioactive Iodine Therapy

Oral

Initially, 300 mg daily.109 For patients with severe hyperthyroidism and/or very large goiters, usual initial dosage may be increased to 400 mg daily;109 occasionally, an initial dosage of 600–900 mg daily may be required.109


Some clinicians recommend continuing therapy at initial dosage for about 6–8 weeks until euthyroidism is achieved; then discontinue propylthiouracil ≥7 days before radioactive iodine therapy.c May reinstitute propylthiouracil 4 days after radioactive iodine therapy as needed (e.g., in patients with cardiac disease).c j


Thyrotoxic Crisis

Oral

Usually, 200 mg every 4–6 hours on the first day.b Once full control of symptoms is achieved, reduce dosage gradually to usual maintenance dosage.b


Special Populations


Hepatic Impairment


No specific dosage recommendations at this time.109


Renal Impairment


No specific dosage recommendations at this time.109


Geriatric Patients


No specific dosage recommendations at this time.109


Pregnancy


If used during pregnancy for the management of hyperthyroidism, a sufficient, but not excessive, dosage is necessary.109 Thyroid dysfunction diminishes in many women as pregnancy proceeds; reduction in dosage may be possible, and, in some patients, propylthiouracil can be discontinued several weeks or months before delivery.109 (See Pregnancy under Cautions and also see Hepatotoxicity under Cautions.)


Cautions for Propylthiouracil


Contraindications



  • Known hypersensitivity to propylthiouracil or any ingredient in the formulation.109 b



Warnings/Precautions


Warnings


Hepatotoxicity

Liver injury (including severe liver injury) resulting in hepatitis, liver failure (including acute liver failure), liver transplantation, or death reported in adult and pediatric patients.100 101 102 103 104 106 107 109 112 (See Boxed Warning.) FDA has concluded that use of propylthiouracil is associated with a higher risk for clinically serious or fatal liver injury compared with methimazole in both adult and pediatric patients.112


No cases of liver failure reported with use of methimazole in pediatric patients; therefore, propylthiouracil not recommended for use in pediatric patients except in rare instances in which methimazole is not well tolerated and surgery or radioactive iodine therapy are not appropriate therapies.109 (See Pediatric Use under Cautions.)


Cases of liver injury, including liver failure and death, reported in women receiving propylthiouracil during pregnancy.109 Two cases of in utero exposure with liver failure and death of a newborn also reported.109 Use of an alternative antithyroid drug (e.g., methimazole) may be advisable after the first trimester of pregnancy.109 (See Fetal/Neonatal Morbidity and also see Pregnancy under Cautions.)


Extent of propylthiouracil-induced hepatitis and true incidence of severe liver injury not known.104 107


Propylthiouracil-induced liver failure may occur at any time during therapy with a sudden onset, rapid progression, and a low chance of reversibility;103 104 liver failure has been observed after 6–450 days of propylthiouracil therapy (median: 120 days).107


Effect of dosage on risk of hepatotoxicity not clearly elucidated;104 however, reported average daily dosage associated with liver failure was approximately 300 mg in both children and adults.107


Closely monitor patients for signs and symptoms of liver injury (e.g., fatigue, weakness, vague abdominal pain, right upper quadrant pain, anorexia, pruritus, easy bruising, jaundice, pruritic rash, light-colored stool, dark urine, joint pain, bloating, nausea), particularly during the first 6 months following initiation of therapy.100 109 112 If such symptoms occur, immediately discontinue the drug, evaluate the patient for evidence of liver injury (including evaluation of liver function [bilirubin, alkaline phosphatase] and hepatocellular integrity [ALT, AST]), and provide supportive care.100 109 Some clinicians state that in patients with thioamide-induced hepatitis, rechallenge with alternative thioamide is not recommended because death has been reported.c


Routine biochemical monitoring of liver function (bilirubin, alkaline phosphatase) and hepatocellular integrity (ALT, AST) may not be effective in identifying patients at risk of liver failure and is not expected to attenuate risk of severe liver injury due to its rapid and unpredictable onset; however, should be performed in symptomatic patients.103 104 107 109


Hematologic Effects

Risk of agranulocytosis;109 b c d f usually occurs within first 3 months of therapy,109 but rarely may occur after 4 months of therapy.b Increased risk in patients >40 years of age;b d use with caution in such patients.b n


Leukopenia, thrombocytopenia, and aplastic anemia (pancytopenia) also may occur.109 b Hypoprothrombinemia and bleeding reported rarely with thioamides.c j (See Laboratory Monitoring under Cautions.)


Monitor patient carefully for signs or symptoms of illness (e.g., sore throat, skin eruptions, fever, chills, headache, general malaise), particularly during the early stages of therapy.b c d If fever, sore throat, or other signs or symptoms of illness occur, determine leukocyte and differential counts to assess whether agranulocytosis has developed.109 b d f When evaluating myelopoietic response to propylthiouracil, consider that leukopenia (i.e., WBC <4000/mm3) occurs in 10% of untreated hyperthyroid patients and is often associated with relative granulocytopenia.109 b


If agranulocytosis, aplastic anemia (pancytopenia), or fever is suspected, discontinue propylthiouracil and initiate appropriate supportive and symptomatic therapy.109 b c Obtain bone marrow indices.109


Hypothyroidism

May cause hypothyroidism necessitating routine monitoring of TSH and free T4 concentrations with dosage adjustments to maintain a euthyroid state.109


May cause fetal goiter and cretinism when administered to a pregnant woman, because the drug readily crosses the placenta.109 (See Fetal/Neonatal Morbidity and also see Pregnancy under Cautions.)


Fetal/Neonatal Morbidity

May cause fetal harm (i.e., induction of goiter, hypothyroidism, or cretinism).109 113 b


Congenital malformations reported approximately 3 times more often with prenatal exposure to methimazole compared with propylthiouracil.112 Distinct and consistent pattern of congenital malformations associated with the use of methimazole, but not with propylthiouracil, particularly craniofacial malformations (e.g., scalp epidermal aplasia [aplasia cutis], facial dysmorphism, choanal atresia).112 Specific birth defects were associated with use of methimazole during the first trimester of pregnancy and not found when the drug was administered later in pregnancy.112 FDA has not found a consistent pattern of birth defects associated with use of propylthiouracil and has concluded there is no convincing evidence of an association between propylthiouracil use and congenital malformations, even with use during the first trimester.112 (See Pregnancy under Cautions and also see Distribution under Pharmacokinetics.)


If used during pregnancy or if pregnancy occurs during therapy, apprise of rare potential hazard to the mother and fetus of liver damage; inform the patient of these potential risks and risks of methimazole-associated fetal malformations when considering antithyroid drug use during pregnancy.104 106 109 (See Hepatotoxicity under Cautions.)


Sensitivity Reactions


Cross-Sensitivity

Cross-sensitivity between thioamides likely to occurc f (i.e., in approximately 50% of patients switched from one thioamide agent to the other).d j


General Precautions


Laboratory Monitoring

Before initiating thioamide therapy, some clinicians recommend obtaining baseline T4 and TSH concentrations.c Baseline WBC with differential also may be useful in evaluating thioamide-induced adverse effects (e.g., leukopenia and/or agranulocytosis).c Routine biochemical monitoring of liver function (bilirubin, alkaline phosphatase) and hepatocellular integrity (ALT, AST) not expected to attenuate risk of severe liver injury, but should be performed in symptomatic patients.103 104 107 109 (See Hepatotoxicity under Cautions.)


Monitor thyroid function periodically109 b (e.g., 4–6 weeks after initiation of therapy and after any dosage adjustmentsc ); decrease dosage if TSH is elevated.109 b Once euthyroidism is achieved, monitor thyroid function every 3–6 months.c


Determine leukocyte and differential counts in patients who develop any signs or symptoms of illness (e.g., fever, sore throat) during therapy.b f


Consider monitoring PT during therapy, particularly before surgical procedures, because of possible risk of hypoprothrombinemia and bleeding.109 b


Dermatologic Effects

Exfoliative dermatitis reported.109 If exfoliative dermatitis is suspected, discontinue propylthiouracil and initiate appropriate supportive and symptomatic therapy.109 b


Immunologic Effects

Vasculitic syndrome associated with the presence of antineutrophil cytoplasmic antibody (ANCA) reported.109 d Manifestations of ANCA-positive vasculitis may include rapidly progressive glomerulonephritis (crescentic and pauci-immune necrotizing glomerulonephritis) sometimes leading to acute renal failure, fever, pulmonary infiltrates or alveolar hemorrhage, arthritis, skin ulcers, and leukocytoclastic vasculitis.109 d If ANCA-positive vasculitis is suspected, discontinue propylthiouracil promptly.109 d


Pulmonary Effects

Interstitial pneumonitis reported.109 b If interstitial pneumonitis is suspected, discontinue propylthiouracil.109


Specific Populations


Pregnancy

Category D.109 h (See Fetal/Neonatal Morbidity under Cautions and also see Distribution under Pharmacokinetics.)


Despite potential fetal hazard, antithyroid agents still considered therapy of choice for management of hyperthyroidism during pregnancy.108 d e Since methimazole may be associated with the rare development of fetal abnormalities (e.g., aplasia cutis, choanal atresia), propylthiouracil may be preferred when an antithyroid drug is indicated during organogenesis, in the first trimester of pregnancy, or just prior to the first trimester of pregnancy.100 103 106 107 108 109 (See Boxed Warning and also see Fetal/Neonatal Morbidity under Cautions.) May be preferable to switch from propylthiouracil to methimazole for the second and third trimesters, because of potential maternal adverse effects of propylthiouracil (e.g., hepatotoxicity).109 (See Hepatotoxicity under Cautions.) Not known if risk of methimazole-induced aplasia cutis or embryopathy outweighs risk of propylthiouracil-induced hepatotoxicity.104


When used in pregnancy, administer lowest effective dosage to maintain T4 concentrations at high end of normal range.108 c d e f As thyroid dysfunction improves during course of pregnancy, may reduce propylthiouracil dosage; in some patients, may discontinue propylthiouracil several weeks or months before delivery.109 b


If used during pregnancy or if patient becomes pregnant while receiving the drug, apprise of rare potential hazard to the mother and fetus of liver damage; inform the patient of these potential risks and risks of methimazole-associated fetal malformations when considering antithyroid drug use during pregnancy.104 106 109


Lactation

Distributed into milk to a small extent and, therefore, likely does not result in clinically important doses to the nursing infant.109 110 d h Mean amount of propylthiouracil distributed into milk during 4 hours following single oral 400-mg dose in 9 lactating women was 0.025% (range: 0.007–0.077%) of the administered dose.109 110 AAP and other clinicians consider propylthiouracil compatible with breast-feeding.108 d f h i


Adult Use

Patients >40 years of age: Use with caution because of increased risk of agranulocytosis.b n (See Hematologic Effects under Cautions.)


Pediatric Use

Postmarketing cases of severe liver injury, including hepatic failure requiring liver transplantation or resulting in death, reported in pediatric patients; however, no such reports observed with methimazole.109 117 Propylthiouracil not recommended for use in pediatric patients except in rare instances in which methimazole is not well tolerated and surgery or radioactive iodine therapy are not appropriate therapies.100 103 106 109 In addition, some experts state that alternative therapy should be considered for children who are currently receiving propylthiouracil and that it is reasonable and prudent to discontinue propylthiouracil use in children receiving this drug for the treatment of Graves’ disease.105 106


When propylthiouracil is used in children, inform parents and patients of risk of liver failure.109 If patients develop tiredness, nausea, anorexia, fever, pharyngitis, or malaise, immediately discontinue the drug, contact a clinician, and obtain WBC count, liver function tests, and transaminase concentrations.109 (See Hepatotoxicity under Cautions.)


Common Adverse Effects


Rash,109 b d f j l urticaria,109 b d pruritus,109 b abnormal hair loss,109 b skin pigmentation,109 b edema,109 b nausea,109 b f l vomiting,109 b l epigastric distress,109 b anorexia,f loss of taste109 b f or smell,f taste perversion,109 arthritis,f arthralgia,109 b d j myalgia,109 b paresthesia,109 b fever,f j l headache,109 b drowsiness,109 b neuritis,109 b vertigo,109 b jaundice,109 b sialadenopathy,109 b lymphadenopathy.109 b


Interactions for Propylthiouracil


Drugs Known to be Associated with Agranulocytosis


Use concomitantly with extreme caution.109 b


Specific Drugs


















Drug



Interaction



Comments



Anticoagulants, oral (e.g., warfarin)



Activity of oral anticoagulants (e.g., warfarin) may be increased because of the potential inhibition of vitamin K activity by propylthiouracil;109 however, increased and decreased PT/INR responses reported with concomitant use of propylthiouracil and warfarin115



Consider additional monitoring of PT/INR, particularly prior to surgery109



β-Adrenergic blocking agents (e.g., propranolol)



Possible increased clearance of β-adrenergic blocking agents with a high extraction ratio during hyperthyroid state109



Reduction of β-blocker dosage may be needed when patient becomes euthyroid109



Digitalis glycosides (e.g., digoxin)



Possible increased serum digitalis concentrations when hyperthyroid patients receiving a stable digitalis glycoside regimen become euthyroid109



Reduction of digitalis glycoside dosage may be needed when patient becomes euthyroid109



Theophylline



Possible decreased theophylline clearance when hyperthyroid patients on a stable theophylline regimen become euthyroid109



Reduction of theophylline dosage may be needed when patient becomes euthyroid109


Propylthiouracil Pharmacokinetics


Absorption


Bioavailability


Rapidly and readily absorbed from the GI tract following oral administration.109 b d j Peak plasma concentrations attained within 1–2 hours;b d j however, plasma concentrations do not appear to correlate with therapeutic effects.b


Bioavailability is approximately 75%.b


Onset

Slow onset because thioamides block synthesis (rather than release) of thyroid hormones; some symptomatic improvement should be noted 2–3 weeks after initiation of therapy.c


Duration

12–24 hours.d


Distribution


Extent


Distribution into human body tissues and fluids not fully characterized; however, drug appears to be concentrated in the thyroid gland.b


Readily crosses the placenta.109 b d e f h (See Fetal/Neonatal Morbidity and also Pregnancy under Cautions.)


Distributed into milk to a small extent;109 b h extent of distribution is about 0.007–0.077% of a single orally administered dose.109 110 111 b (See Lactation under Cautions.)


Plasma Protein Binding

Approximately 80–90%.d h


Elimination


Metabolism


Extensively metabolized to its glucuronide conjugate and other minor metabolites.109 b


Elimination Route


35% of dose excreted in urine as unchanged drug and metabolites within 24 hours.109 b


Half-life


Approximately 1–2 hours.b c d


Stability


Storage


Oral


Tablets

15–30°C.109


Actions



  • Inhibits the synthesis of thyroid hormones109 d f h l by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin;b j also inhibits the coupling of these iodotyrosyl residues to form iodothyronine. b


    Exact mechanism(s) not fully elucidated; however, propylthiouracil may interfere with the oxidation of iodide ion and iodotyrosyl groups.b




  • Limited evidence suggests that coupling reaction is more sensitive to antithyroid agents than the iodination reaction.b




  • Does not inhibit the action of thyroid hormones already formed and present in the thyroid gland or circulation; also does not interfere with the effectiveness of exogenously administered thyroid hormones.109 b Patients whose thyroid gland contains relatively high concentration of iodine (e.g., from prior ingestion or from administration during diagnostic radiologic procedures) may respond relatively slowly to antithyroid agents.b




  • Inhibits peripheral deiodination of T4 to T3.109 b c f h j



Advice to Patients



  • Under terms of FDA-approved REMS program, a medication guide must be dispensed with every propylthiouracil prescription.112 113 114 Importance of patient reading the manufacturer’s medication guide prior to initiating therapy with the drug and each time the prescription is refilled.112 113




  • Risk of liver failure.100 103 109 112 Importance of immediately discontinuing the drug and promptly contacting clinicians if signs and symptoms of liver injury or hepatic dysfunction (e.g., fatigue, weakness, vague abdominal pain, right upper quadrant pain, loss of appetite, itching, easy bruising, yellowing of the eyes or skin, pruritic rash, light-colored stool, dark urine, joint pain, bloating, nausea) occur, particularly in the first 6 months of therapy.100 103 109 112 (See Hepatotoxicity under Cautions.)




  • Importance of informing a clinician immediately if signs or symptoms of illness (e.g., sore throat, skin eruptions, fever, chills, headache, general malaise) occur.109 b c j (See Hematologic Effects under Cautions.)




  • Importance of patient not discontinuing propylthiouracil therapy unless instructed by their clinician.112




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.109




  • Importance of women immediately informing clinicians if they are or plan to become pregnant or plan to breast-feed.109 112 Necessity for clinicians to advise women of rare potential hazard to the mother and fetus of propylthiouracil-associated liver toxicity, as well as risks of methimazole-associated fetal malformations when considering antithyroid drug use during pregnancy.104 106 109 (See Fetal/Neonatal Morbidity and also see Hepatotoxicity under Cautions.)




  • Importance of informing patients of other important precautionary information.109 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name













Propylthiouracil

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets



50 mg*



Propylthiouracil Tablets


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 10/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Propylthiouracil 50MG Tablets (WEST-WARD): 90/$20.99 or 180/$34.97



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions October 27, 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.


† Use is not currently included in the labeling approved by the US Food and Drug Administration.




References



100. Food and Drug Administration. FDA Alert: Propylthiouracil-induced liver failure. Rockville, MD; 2009 Jun 4. From FDA website. Accessed 2009 Oct 28.



101. Food and Drug Administration. FDA News Release: FDA warns about serious liver injury associated with anti-thyroid drug. Rockville, MD; 2009 Jun 3. From FDA website. Accessed 2009 Oct 30.



102. Russo MW, Galanko JA, Shrestha R et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004; 10:1018-23. [PubMed 15390328]



103. Bahn RS, Burch HS, Cooper DS et al. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid. 2009; 19:673-4. [PubMed 19583480]



104. Eunice Kennedy Shriver National Institute of Child Health and Human Development. Hepatic toxicity following treatment for pediatric Graves’ disease meeting: October 28, 2008. Conference proceeding. Available from website. Accessed 2009 Oct 30.



105. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009; 360:1574-5. [PubMed 19357418]



106. Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatotoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol. 2009. Article ID 132041. DOI:10.1155/2009/132041.



107. Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab. 2009; 94:1881-2. [PubMed 19401361]



108. Abalovich M, Amino N, Barbour LA et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2007; 92:S1-47. [PubMed 17948378]



109. Dava Pharmaceuticals, Inc. Propylthiouracil tablets prescribing information. Fort Lee, NJ; 2010 Jan.



110. Kampmann JP, Johansen K, Hansen JM et al. Propylthiouracil in human milk. Revision of a dogma. Lancet. 1980; 1:736-7. [PubMed 6103158]



111. Low LC, Lang J, Alexander WD. Excretion of carbimazole and propylthiouracil in breast milk. Lancet. 1979; 2:1011. [PubMed 91730]



112. Food and Drug Administration. FDA drug safety communication: New boxed warning on severe liver injury with propylthiouracil. Rockville, MD; 2010 Apr 21. Available from FDA website (). Accessed 2010 Sep 8.



113. Dava Pharmaceuticals, Inc. Propylthiouracil tablets medication guide. Fort Lee, NJ; 2010 Mar.



114. Dava Pharmaceuticals, Inc. Propylthiouracil risk evaluation and mitigation strategy (REMS). Fort Lee, NJ; 2010 Mar 24. Available from FDA website (). Accessed 2010 Sep 8.



115. Bristol-Myers Squibb. Coumadin (warfarin sodium) tablets crystalline and Coumadin (warfarin sodium) for injection prescribing information. Princeton, NJ; 2010 Jan.



116. Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev. 2005; :CD002800. [PubMed 16235302]



117. Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab. 2010; 95:3260-7. [PubMed 20427502]



b. AHFS drug information 2011. McEvoy GK, ed. Propylthiouracil. Bethesda, MD: American Society of Health-System Pharmacists; 2011.



c. Dong BJ. Endocrine Disorders. In: Koda-Kimble MA, Young LY, Kradjan WA et al, eds. Applied therapeutics: the clinical use of drugs. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.



d. Anon. Drugs for hypothyroidism and hyperthyroidism. Treat Guidel Med Lett. 2006; 4:17-24.



e. American Association of Clinical Endocrinologists. Medical

Wednesday, 4 July 2012

ApexiCon


Generic Name: diflorasone topical (dye FLOR a sone)

Brand Names: ApexiCon, ApexiCon E, Maxiflor, Psorcon E


What is ApexiCon (diflorasone topical)?

Diflorasone is a topical (for the skin) steroid. It reduces the actions of chemicals in the body that cause inflammation, redness, and swelling.


Diflorasone topical is used to treat the inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis.


Diflorasone topical may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about ApexiCon (diflorasone topical)?


Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.


Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to. Plastic film covering (such as plastic wrap) is sometimes used when treating psoriasis. Follow your doctor's instructions.

If you are treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Covering the skin that is treated with diflorasone topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects.


Do not use this medication on a child without a doctor's advice. Children are more likely to absorb large amounts of a topical steroid through the skin. Steroid absorption in children may cause unwanted side effects, or a delay in growth with long-term use. Talk with your doctor if you think your child is not growing at a normal rate while using this medication over a long treatment period. Contact your doctor if your condition does not improve, or if you develop signs of a bacterial, fungal, or viral skin infection.

What should I discuss with my healthcare provider before using ApexiCon (diflorasone topical)?


Do not use this medication if you are allergic to diflorasone.

Before using diflorasone topical, tell your doctor if you are allergic to any drugs, or if you have any type of skin infection.


Also tell your doctor if you have diabetes. Topical steroid medicines absorbed through the skin may increase the glucose (sugar) levels in your blood or urine.


FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether diflorasone topical passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Do not use this medication on a child without a doctor's advice. Children are more likely to absorb large amounts of a topical steroid through the skin. Steroid absorption in children may cause unwanted side effects, or a delay in growth with long-term use. Talk with your doctor if you think your child is not growing at a normal rate while using this medication over a long treatment period.

How should I use ApexiCon (diflorasone topical)?


Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.


Wash your hands before and after using diflorasone topical, unless you are using the medication to treat the skin on your hands.

Apply a small amount to the affected area and rub it gently into the skin. Do not use this medication over a large area of skin.


Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to. Plastic film covering (such as plastic wrap, plastic gloves, or a shower cap) is sometimes used to cover areas of psoriasis that are treated with diflorasone topical. Follow your doctor's instructions.

Avoid plastic covering over skin lesions that are oozing or draining pus or any type of fluid.


If you are treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Covering the skin that is treated with diflorasone topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects.


Contact your doctor if your condition does not improve, or if you develop signs of a bacterial, fungal, or viral skin infection. It is important to use diflorasone topical regularly to get the most benefit.

If you are treating psoriasis, use the medication for at least a few days after the skin clears. Stopping too soon could cause a relapse.


To be sure this medication is not causing harmful effects with long-term use, you may need blood tests. Do not miss any scheduled appointments.


Store diflorasone topical at room temperature away from moisture and heat. Keep from freezing.

What happens if I miss a dose?


Use the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and use the medicine at the next regularly scheduled time. Do not use extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine.

An overdose of diflorasone is not expected to produce life-threatening symptoms. However, long-term use of high steroid doses can lead to symptoms such as thinning skin, easy bruising, changes in the shape or location of body fat (especially in your face, neck, back, and waist), increased acne or facial hair, menstrual problems, impotence, or loss of interest in sex.


What should I avoid while using ApexiCon (diflorasone topical)?


Diflorasone topical should not be used to treat any skin condition your doctor has not prescribed it for.


Avoid getting this medication in your eyes. If contact does occur, rinse with water. Do not use diflorasone topical on broken or infected skin. Also avoid using this medication in open wounds.

ApexiCon (diflorasone topical) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have severe irritation of any treated skin, or if you show signs of absorbing diflorasone topical through your skin, such as:

  • blurred vision, or seeing halos around lights;




  • mood changes;




  • sleep problems (insomnia);




  • weight gain, puffiness in your face; or




  • muscle weakness, feeling tired.



Less serious side effects may include:



  • mild skin itching, burning, or dryness;




  • thinning or softening of your skin;




  • skin rash or irritation around your mouth;




  • swollen hair follicles;




  • changes in color of treated skin;




  • blisters, pimples, or crusting of treated skin; or




  • stretch marks.



This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect ApexiCon (diflorasone topical)?


It is not likely that other drugs you take orally or inject will have an effect on topically applied diflorasone topical. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More ApexiCon resources


  • ApexiCon Side Effects (in more detail)
  • ApexiCon Use in Pregnancy & Breastfeeding
  • ApexiCon Drug Interactions
  • ApexiCon Support Group
  • 0 Reviews for ApexiCon - Add your own review/rating


  • Apexicon Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Apexicon Prescribing Information (FDA)

  • Apexicon Advanced Consumer (Micromedex) - Includes Dosage Information

  • Apexicon E Prescribing Information (FDA)

  • Florone Prescribing Information (FDA)

  • Psorcon Monograph (AHFS DI)

  • psorcon Prescribing Information (FDA)



Compare ApexiCon with other medications


  • Atopic Dermatitis
  • Eczema
  • Psoriasis
  • Skin Rash
  • Urticaria


Where can I get more information?


  • Your pharmacist can provide more information about diflorasone topical.

See also: ApexiCon side effects (in more detail)


Tuesday, 3 July 2012

Methotrexate 25mg / ml solution for injection (hameln)






Read all of this patient information leaflet carefully; it contains important information about the drug.



  • Keep this leaflet. You may need to read it again.

  • If you have further questions, please ask your doctor or your pharmacist.

  • This product has been prescribed for you personally and must not be passed on to anyone else.




In this leaflet:



  • 1. What Methotrexate 25 mg/ml solution for injection is and what it is used for

  • 2. Before receiving Methotrexate 25 mg/ml solution for injection

  • 3. How Methotrexate 25 mg/ml solution for injection is administered

  • 4. Possible side effects

  • 5. Storing Methotrexate 25 mg/ml solution for injection



Methotrexate 25 mg/ml solution for injection



Each 1 ml of this sterile solution for injection contains methotrexate sodium equivalent to 25 milligrams of active
substance methotrexate.



Other ingredients are sodium hydroxide, sodium chloride, water for injections and nitrogen.





Marketing Authorisation Holder:





hameln pharma plus gmbh

Langes Feld 13

31789 Hameln

Germany





Manufacturer:




Haupt Pharma Wolfratshausen GmbH

Pfaffenrieder Str. 5

82515 Wolfratshausen

Germany





Distributor:




hameln pharmaceuticals ltd

Gloucester

UK





What Methotrexate 25 mg/ml solution for injection is and what it is used for



Methotrexate 25 mg/ml solution for injection is a yellow and sterile solution in clear glass vials.



Methotrexate is one of a group of medicines known as antimetabolites. It is used in the treatment of cancer as well as psoriasis including psoriatic arthritis. It stops a substance called dihydrofolate reductase from working. This substance is an enzyme, which is important in “cell growth (replication)”. By inhibiting the enzyme, cancer cells will eventually “die”.



Methotrexate helps patients with psoriasis by killing the cells in the skin that are growing too fast. It is these rapidly growing cells that cause the raised patches of skin in psoriasis.



Pack sizes:




The solution for injection is available in



  • packs of 1, 5 or 10 vial(s) containing 2 ml solution. This corresponds to 50 mg of active substance methotrexate per vial.

  • packs of 1, 5 or 10 vial(s) containing 20 ml solution. This corresponds to 500 mg of active substance methotrexate per vial.

  • packs of 1 or 5 vial(s) containing 40 ml solution. This corresponds to 1,000 mg of active substance methotrexate per vial.

  • a pack of 1 vial containing 200 ml solution. This corresponds to 5,000 mg of active substance methotrexate per vial.





Before receiving Methotrexate 25 mg/ml solution for injection




1 You should not receive Methotrexate 25 mg/ml solution for injection



  • if you have ever had any allergic reaction to methotrexate or any of the ingredients of this product

  • if you have severe problems with your kidneys

  • if you have severe problems with your liver, including alcoholic liver disease, abnormal blood counts, fibrosis, cirrhosis or recent active hepatitis

  • if you suffer from alcoholism

  • if you have any serious blood disorders (anaemia, a reduction in white cell number (leucopenia) or platelet number (thrombocytopenia))

  • if you have an active infection

  • if you have a medical condition, or are receiving medication, which lowers your resistance to infection

  • if you are pregnant or intend to become pregnant, or are breast-feeding, as the drug can harm unborn and breast-fed infants.




2 Take special care with Methotrexate 25 mg/ml solution for injection



  • if you have impaired respiratory function

  • if you have mild to moderate kidney or liver problems, or a mild to moderate blood disorder

  • if you have diarrhoea

  • if you have ulcers in your mouth, stomach or intestine (large bowel)

  • if you have ascites (collection of liquid in the free abdominal cavity) and/or pleural effusions (collection of liquid in the pleural cavity)

  • if you are receiving or intend to receive any vaccine, as methotrexate can reduce their effect

  • if you have had radio- or chemotherapy before (especially of the pelvis), or are receiving radiotherapy concurrently

  • if you have an impaired general condition (if you feel weak or infirm)

  • if you are of advanced age

  • if Methotrexate 25 mg/ml solution for injection is given to very young children.

Please consult your doctor, even if these statements were applicable to you at any time in the past.





3 Interactions with other drugs



Please inform your doctor if you are taking or have recently taken any other medicines, even those not prescribed.



Medications which can be influenced by or can influence the effect of methotrexate negatively:



  • pain-killers such as salicylates (e.g. aspirin), amidopyrine derivatives, phenylbutazone and leflunomide

  • diphenylhydantoins (e.g. phenytoin, an antiepileptic agent)

  • barbiturates and tranquillisers (sedative agents)

  • antibiotics (medication against bacteria), e.g. tetracyclines, penicillins, chloramphenicol, cotrimoxazole and sulphonamides

  • cytostatics (medication against cancer), e.g. doxorubicin, mercaptopurine, procarbazine, cisplatin, L-asparaginase and 5-fluorouracil

  • Disease-modifying antirheumatic drugs (DMARD; drugs that are used to treat rheumatoid arthritis)

  • probenecid (uricosuric agent used in the prophylaxis of gout)

  • p-aminobenzoic acid (used in sun creams)

  • non-steroidal anti-inflammatory drugs (NSAIDs; medications against "rheumatism", e.g. indomethacin, ibuprofen)

  • anti-folate drugs (e.g. nitrous oxide or co-trimoxazole)

  • p-aminohippuric acid (substance to check kidney function)

  • pyrimethamine (medication against malaria)

  • cholestyramine (lipid-lowering agent)

  • acitretin or other retinoids (for psoriasis or skin disorders)

  • theophylline (used mainly in bronchial asthma)

  • erythrocyte concentrates (for blood transfusion)

  • nitrous oxide-based anaesthetics

  • omeprazole (used in the therapy of gastric ulcers)

  • sulphasalazine (for ulcerative colitis)

  • tetrahydrofolic acid preparations

  • oral antidiabetics (medications to treat diabetes) and diuretics (increase urine output)

  • hypoglycaemics (lower blood sugar levels)

  • other medicinal products with nephrotoxic and hepatotoxic potential (incl. alcohol)

  • vaccinations

  • azathioprine (an immunosuppressive drug)

  • vitamin preparations containing folic acid or its derivates

Please note that these statements may also apply to products used some time ago or at some time in the future.





4 Pregnancy



Do not take Methotrexate 25 mg/ml solution for injection if you are pregnant because it causes a variety of malformations or even the death of the foetus. Women must not get pregnant during treatment with Methotrexate 25 mg/ml solution for injection. If you get pregnant during treatment with Methotrexate 25 mg/ml solution for injection, please inform your doctor immediately!



Special indications for contraception:



Methotrexate temporarily influences sperm and egg production. During treatment and up to 6 months after treatment is stopped, you must practice effective contraception. In this respect, it is of no importance whether the male or the female partner takes Methotrexate 25 mg/ml solution for injection!





5 Breast-feeding



Do not take Methotrexate 25 mg/ml solution for injection during breast-feeding, since methotrexate is excreted into the breast milk. Methotrexate can seriously harm breastfed infants.






How Methotrexate 25 mg/ml solution for injection is administered



Your doctor or nurse will give you Methotrexate 25 mg/ ml solution for injection injecting it either into the central nervous system (intraventricular or intrathecal administration only for the 2 ml vial), into one of your veins (e.g. as bolus or infusion), arteries, or a muscle.



During your treatment, you will have a number of tests, such as regular blood tests to check that appropriate blood levels of methotrexate are attained and that your kidneys are eliminating excess drug properly. Other tests are performed routinely at the start and during the course of therapy (e.g. chest X-ray, liver function test, full blood count and urinalysis).



Your doctor may instruct you to take sodium bicarbonate or acetazolamide tablets while receiving your injections to help make sure that methotrexate is not concentrated in the kidneys. If you receive methotrexate in high doses, you will receive calcium folinate as well to lessen the side effects of methotrexate. Your doctor will decide on a suitable dose for you. Doses vary considerably and will depend on the underlying disease. It is possible that you will only get methotrexate. In the case of cancer, it is also possible that you will receive so-called combination therapy in which you must take several medications. Your body weight, age, general condition of health, your response to the drug and whether other medicines are required at the same time will also influence the dose you receive.





Possible Side Effects



Like all medicines Methotrexate 25 mg/ml solution for injection can have side effects:



Methotrexate has the potential for serious, sometimes fatal toxicity. Because the toxic reactions can occur at any time during therapy, your doctor should observe you closely and must inform you of early signs and symptoms of toxicity.



If you think you have an infection, a sore throat, fever or chills during treatment, you should tell your doctor
immediately.



The most common undesirable effects are ulcerative stomatitis, leucopenia, nausea, and abdominal discomfort.




Unwanted effects of Methotrexate 25 mg/ml solution for injection are



  • Blood picture changes - e.g. your vulnerability for infections may increase, you may suffer from unusual bleeding or bruising and you may observe signs of anaemia (weakness, tiredness, difficulties in breathing)


  • disorders of the mouth, stomach and intestines like mucositis (mucus membrane inflammation, e.g. inflammation of the gums, tongue, throat, mouth, intestines as well as ulcerations), lack of appetite, feeling sick, vomiting, diarrhoea, unusual bleeding from the mouth, stomach and intestines, inflammation of the pancreas, increased risk of perforation, melaena (red to black stools), malabsorption (disturbances of uptake of nutrition with consequences such as body weight loss), and toxic megacolon (severe complication with massive dilatation of the colon and severe pain, for example)


  • renal failure, impairment of renal function, inflammation of the urinary bladder, blood in the urine, reduced or faulty formation of sperm and egg cells, menstrual dysfunction (periods may become less frequent or even stop completely), infertility, abortion, malformations of the foetus and pain or difficulty in passing urine


  • damage to the liver such as fibrosis (increase in the connective tissue), cirrhosis (transformation of the tissue with hardening and abolition of the normal structure of the organ), hepatitis (inflammation of the liver), acute liver cell death, fatty degeneration of the liver or other histologic (tissue) changes in the liver


  • damage to the lungs such as inflammation and fibrosis (increase in the connective tissue); the pulmonary toxicity may manifest as fever, cough (especially dry and nonproductive), difficulties or increase in the frequency of breathing, chest pain, hypoxaemia (lack of oxygen in the blood), and/or abnormal findings on chest radiography and/or tests of respiratory function, and infections.


  • adverse reactions of the skin such as formation of blisters, becoming red and inflamed, loss of skin tissue, vasculitis (inflammation of blood vessels), rash, itching, nettle rash, photosensitivity, pigmentary changes (discolouration of the skin), telangiectasia (expansion of small superficial blood vessels in the skin), acne,
    formation of boils, point-like or small flat bleeding, an increase in rheumatic nodules, loss of hair, worsening of psoriasis (with concomitant UV therapy), increased colouration or inflammation or detachment of the nails, a "recall" of radiation dermatitis (inflammation of the skin) and sunburn


  • leucoencephalopathy (inflammation of the brain), manifested by ventricular enlargement (expansion of the fluid spaces inside the brain), confusion, shaking, irritability, sleepiness, ataxia (disturbance of balance and co-ordination), dementia, feeling sick, fever, and occasionally seizures or coma, significant intellectual deficit, headache, drowsiness, speech disorder, incomplete palsy affecting one or both sides of the body, fits, dizziness, vomiting, mental disturbance,
    pain, muscle weakness, paraesthesia (pins-and needles sensation), subtle cognitive dysfunction (easily disturbed attention), mood swings, unusual sensations in the head, and even death


  • unwanted reactions of the eyes like swelling, inflammation of the eyelid edges, conjunctivitis (inflammation of the eye conjunctiva), unusual formation of tears, photophobia, and impairment of vision


  • allergic reactions, cerebral oedema (swelling of the brain), haematoma, nodulosis (formation of nodules under the skin), loss of interest in sex / impotence, chills, fever without any detectable cause, decreased resistance to infection, upper respiratory tract infection, abnormal tissue cell changes, metabolic disorders, hyperuricaemia (increased blood levels of uric acid, possibly leading to gout), diabetes, osteoporosis and other bone disorders, including aseptic necrosis of the femoral head (loss of bone tissue in the hip joint), pains in the joints, muscle pain, malaise and undue fatigue, development of the breast gland in males, ringing in the ears, sweating, vaginal discomfort, in rare cases
    pericarditis (inflammation of the outer lining of the heart), pericardial effusion and tamponing (collection of fluid and blood, respectively, in the space between the outer lining of the heart and the heart muscle), low blood pressure, complications resulting from the formation of blood clots in veins and arteries, tumour lysis syndrome (renal failure due to massive destruction of rapidly growing tumour cells) and even sudden death


  • in cases of acute lymphocytic leukaemia, methotrexate can cause pain in the left epigastric region (the area overlying the stomach, below the left lower border of the rib cage; inflammation of the space above the spleen due to destruction of the leukaemic cells)


  • other possible complications from administration into the central nervous system include Guillain-Barré syndrome (inflammation of the central nervous system), nerve palsies, and cerebellar dysfunction, arachnoiditis (inflammation of one of the membranes surrounding the spinal cord) manifested as headache, back pain, neck stiffness, and/or fever, subacute myelopathy (disorder affecting the spinal cord) manifested as complete or incomplete palsy of the lower limbs (paraparesis or paraplegia).

There have been reports on the manifestation of lymphomas which were, in some cases, reversible after discontinuing methotrexate therapy. The potential of methotrexate to produce other cancers in humans has been evaluated in several studies, but the results do not confirm a cancerogenic risk.



You should inform your doctor immediately if you notice any unwanted effects.




If you notice any side effects not mentioned in this patient information leaflet, or if you are unsure of the effect of this product, please consult your doctor or pharmacist.





Storing Methotrexate 25 mg/ml solution for injection



  • Keep the medicine out of the reach and sight of children.

  • Keep the vial in the outer carton in order to protect from light.

  • Do not store above 25°C.

  • For single dose use only. Discard any unused solution immediately and safely after initial use.

  • This medicine should only be administered by a medically qualified person, e.g. a doctor.

  • Methotrexate 25 mg/ml solution for injection should not be used after the expiry date printed on the label.

  • Any unused product or waste should be disposed of in accordance with local requirements for example by incineration.

Remember this medicine is for you only. Only a doctor or a nurse can give you the injection.




Date of last revision of the text: April 2008



721 458 UK 2






Humulin 50/50



insulin human

Dosage Form: injection, suspension
HUMULIN® 50/50

50% HUMAN INSULIN

ISOPHANE SUSPENSION

AND

50% HUMAN INSULIN INJECTION

(rDNA ORIGIN)

100 UNITS PER ML (U-100)

INFORMATION FOR THE PATIENT

10 mL Vial (1000 Units per vial)


WARNINGS


THIS LILLY HUMAN INSULIN PRODUCT DIFFERS FROM ANIMAL–SOURCE INSULINS BECAUSE IT IS STRUCTURALLY IDENTICAL TO THE INSULIN PRODUCED BY YOUR BODY’S PANCREAS AND BECAUSE OF ITS UNIQUE MANUFACTURING PROCESS.


ANY CHANGE OF INSULIN SHOULD BE MADE CAUTIOUSLY AND ONLY UNDER MEDICAL SUPERVISION. CHANGES IN STRENGTH, MANUFACTURER, TYPE (E.G., REGULAR, NPH, ANALOG), SPECIES, OR METHOD OF MANUFACTURE MAY RESULT IN THE NEED FOR A CHANGE IN DOSAGE.


SOME PATIENTS TAKING HUMULIN® (HUMAN INSULIN, rDNA ORIGIN) MAY REQUIRE A CHANGE IN DOSAGE FROM THAT USED WITH OTHER INSULINS. IF AN ADJUSTMENT IS NEEDED, IT MAY OCCUR WITH THE FIRST DOSE OR DURING THE FIRST SEVERAL WEEKS OR MONTHS.


DIABETES


Insulin is a hormone produced by the pancreas, a large gland that lies near the stomach. This hormone is necessary for the body’s correct use of food, especially sugar. Diabetes occurs when the pancreas does not make enough insulin to meet your body’s needs.


To control your diabetes, your doctor has prescribed injections of insulin products to keep your blood glucose at a near–normal level. You have been instructed to test your blood and/or your urine regularly for glucose. Studies have shown that some chronic complications of diabetes such as eye disease, kidney disease, and nerve disease can be significantly reduced if the blood sugar is maintained as close to normal as possible. The American Diabetes Association recommends that if your pre–meal glucose levels are consistently above 130 mg/dL or your hemoglobin A1c (HbA1c) is more than 7%, you should talk to your doctor. A change in your diabetes therapy may be needed. If your blood tests consistently show below–normal glucose levels, you should also let your doctor know. Proper control of your diabetes requires close and constant cooperation with your doctor. Despite diabetes, you can lead an active and healthy life if you eat a balanced diet, exercise regularly, and take your insulin injections as prescribed by your doctor.


Always keep an extra supply of insulin as well as a spare syringe and needle on hand. Always wear diabetic identification so that appropriate treatment can be given if complications occur away from home.


50/50 HUMAN INSULIN


Description


Humulin is synthesized in a special non–disease–producing laboratory strain of Escherichia coli bacteria that has been genetically altered to produce human insulin. Humulin 50/50 is a mixture of 50% Human Insulin Isophane Suspension and 50% Human Insulin Injection (rDNA origin). It is an intermediate-acting insulin combined with the more rapid onset of action of Regular human insulin. The duration of activity may last up to 24 hours following injection. The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual. As with all insulin preparations, the duration of action of Humulin 50/50 is dependent on dose, site of injection, blood supply, temperature, and physical activity. Humulin 50/50 is a sterile suspension and is for subcutaneous injection only. It should not be used intravenously or intramuscularly. The concentration of Humulin 50/50 is 100 units/mL (U–100).


Identification


Human insulin from Eli Lilly and Company has the trademark Humulin. Your doctor has prescribed the type of insulin that he/she believes is best for you.


DO NOT USE ANY OTHER INSULIN EXCEPT ON YOUR DOCTOR’S ADVICE AND DIRECTION.


Always check the carton and the bottle label for the name and letter designation of the insulin you receive from your pharmacy to make sure it is the same as prescribed by your doctor.


Always check the appearance of your bottle of Humulin 50/50 before withdrawing each dose. Before each injection the Humulin 50/50 bottle must be carefully shaken or rotated several times to completely mix the insulin. Humulin 50/50 suspension should look uniformly cloudy or milky after mixing. If not, repeat the above steps until contents are mixed.


Do not use Humulin 50/50:



  • if the insulin substance (the white material) remains at the bottom of the bottle after mixing or




  • if there are clumps in the insulin after mixing, or




  • if solid white particles stick to the bottom or wall of the bottle, giving a frosted appearance.



If you see anything unusual in the appearance of Humulin 50/50 suspension in your bottle or notice your insulin requirements changing, talk to your doctor.


Storage


Not in-use (unopened): Humulin 50/50 bottles not in-use should be stored in a refrigerator, but not in the freezer.


In-use (opened): The Humulin 50/50 bottle you are currently using can be kept unrefrigerated as long as it is kept as cool as possible [below 86°F (30°C)] away from heat and light.


Do not use Humulin 50/50 after the expiration date stamped on the label or if it has been frozen.


INSTRUCTIONS FOR INSULIN VIAL USE


NEVER SHARE NEEDLES AND SYRINGES.


Correct Syringe Type


Doses of insulin are measured in units. U–100 insulin contains 100 units/mL (1 mL=1 cc). With Humulin 50/50, it is important to use a syringe that is marked for U–100 insulin preparations. Failure to use the proper syringe can lead to a mistake in dosage, causing serious problems for you, such as a blood glucose level that is too low or too high.


Syringe Use


To help avoid contamination and possible infection, follow these instructions exactly.


Disposable syringes and needles should be used only once and then discarded by placing the used needle in a puncture-resistant disposable container. Properly dispose of the puncture-resistant container as directed by your Health Care Professional.


Preparing the Dose



  1. Wash your hands.




  2. Carefully shake or rotate the bottle of insulin several times to completely mix the insulin.




  3. Inspect the insulin. Humulin 50/50 suspension should look uniformly cloudy or milky. Do not use Humulin 50/50 if you notice anything unusual in its appearance.




  4. If using a new Humulin 50/50 bottle, flip off the plastic protective cap, but do not remove the stopper. Wipe the top of the bottle with an alcohol swab.




  5. Draw an amount of air into the syringe that is equal to the Humulin 50/50 dose. Put the needle through rubber top of the Humulin 50/50 bottle and inject the air into the bottle.




  6. Turn the Humulin 50/50 bottle and syringe upside down. Hold the bottle and syringe firmly in one hand and shake gently.




  7. Making sure the tip of the needle is in the Humulin 50/50 suspension, withdraw the correct dose of Humulin 50/50 into the syringe.




  8. Before removing the needle from the Humulin 50/50 bottle, check the syringe for air bubbles. If bubbles are present, hold the syringe straight up and tap its side until the bubbles float to the top. Push the bubbles out with the plunger and then withdraw the correct dose.




  9. Remove the needle from the bottle and lay the syringe down so that the needle does not touch anything.



Injection Instructions



  1. To avoid tissue damage, choose a site for each injection that is at least 1/2 inch from the previous injection site. The usual sites of injection are abdomen, thighs, and arms.




  2. Cleanse the skin with alcohol where the injection is to be made.




  3. With one hand, stabilize the skin by spreading it or pinching up a large area.




  4. Insert the needle as instructed by your doctor.




  5. Push the plunger in as far as it will go.




  6. Pull the needle out and apply gentle pressure over the injection site for several seconds. Do not rub the area.




  7. Place the used needle in a puncture-resistant disposable container and properly dispose of the puncture-resistant container as directed by your Health Care Professional.



DOSAGE


Your doctor has told you which insulin to use, how much, and when and how often to inject it. Because each patient’s diabetes is different, this schedule has been individualized for you. Your usual dose of Humulin 50/50 may be affected by changes in your diet, activity, or work schedule. Carefully follow your doctor’s instructions to allow for these changes. Other things that may affect your Humulin 50/50 dose are:


Illness


Illness, especially with nausea and vomiting, may cause your insulin requirements to change. Even if you are not eating, you will still require insulin. You and your doctor should establish a sick day plan for you to use in case of illness. When you are sick, test your blood glucose frequently. If instructed by your doctor, test your ketones and report the results to your doctor.


Pregnancy


Good control of diabetes is especially important for you and your unborn baby. Pregnancy may make managing your diabetes more difficult. If you are planning to have a baby, are pregnant, or are nursing a baby, talk to your doctor.


Medication


Insulin requirements may be increased if you are taking other drugs with blood–glucose–raising activity, such as oral contraceptives, corticosteroids, or thyroid replacement therapy. Insulin requirements may be reduced in the presence of drugs that lower blood glucose or affect how your body responds to insulin, such as oral antidiabetic agents, salicylates (for example, aspirin), sulfa antibiotics, alcohol, certain antidepressants and some kidney and blood pressure medicines. Your Health Care Professional may be aware of other medications that may affect your diabetes control. Therefore, always discuss any medications you are taking with your doctor.


Exercise


Exercise may lower your body’s need for insulin during and for some time after the physical activity. Exercise may also speed up the effect of an insulin dose, especially if the exercise involves the area of injection site (for example, the leg should not be used for injection just prior to running). Discuss with your doctor how you should adjust your insulin regimen to accommodate exercise.


Travel


When traveling across more than 2 time zones, you should talk to your doctor concerning adjustments in your insulin schedule.


COMMON PROBLEMS OF DIABETES


Hypoglycemia (Low Blood Sugar)


Hypoglycemia (too little glucose in the blood) is one of the most frequent adverse events experienced by insulin users. It can be brought about by:



  1. Missing or delaying meals.




  2. Taking too much insulin.




  3. Exercising or working more than usual.




  4. An infection or illness associated with diarrhea or vomiting.




  5. A change in the body’s need for insulin.




  6. Diseases of the adrenal, pituitary, or thyroid gland, or progression of kidney or liver disease.




  7. Interactions with certain drugs, such as oral antidiabetic agents, salicylates (for example, aspirin), sulfa antibiotics, certain antidepressants and some kidney and blood pressure medicines.




  8. Consumption of alcoholic beverages.



Symptoms of mild to moderate hypoglycemia may occur suddenly and can include:

























  • sweating





  • drowsiness





  • dizziness





  • sleep disturbances





  • palpitation





  • anxiety





  • tremor





  • blurred vision





  • hunger





  • slurred speech





  • restlessness





  • depressed mood





  • tingling in the hands, feet, lips, or tongue





  • irritability





  • lightheadedness





  • abnormal behavior





  • inability to concentrate





  • unsteady movement





  • headache





  • personality changes



Signs of severe hypoglycemia can include:









  • disorientation





  • seizures





  • unconsciousness





  • death



Therefore, it is important that assistance be obtained immediately.


Early warning symptoms of hypoglycemia may be different or less pronounced under certain conditions, such as long duration of diabetes, diabetic nerve disease, use of medications such as beta–blockers, changing insulin preparations, or intensified control (3 or more insulin injections per day) of diabetes.


A few patients who have experienced hypoglycemic reactions after transfer from animal–source insulin to human insulin have reported that the early warning symptoms of hypoglycemia were less pronounced or different from those experienced with their previous insulin.


Without recognition of early warning symptoms, you may not be able to take steps to avoid more serious hypoglycemia. Be alert for all of the various types of symptoms that may indicate hypoglycemia. Patients who experience hypoglycemia without early warning symptoms should monitor their blood glucose frequently, especially prior to activities such as driving. If the blood glucose is below your normal fasting glucose, you should consider eating or drinking sugar–containing foods to treat your hypoglycemia.


Mild to moderate hypoglycemia may be treated by eating foods or drinks that contain sugar. Patients should always carry a quick source of sugar, such as hard candy or glucose tablets. More severe hypoglycemia may require the assistance of another person. Patients who are unable to take sugar orally or who are unconscious require an injection of glucagon or should be treated with intravenous administration of glucose at a medical facility.


You should learn to recognize your own symptoms of hypoglycemia. If you are uncertain about these symptoms, you should monitor your blood glucose frequently to help you learn to recognize the symptoms that you experience with hypoglycemia.


If you have frequent episodes of hypoglycemia or experience difficulty in recognizing the symptoms, you should talk to your doctor to discuss possible changes in therapy, meal plans, and/or exercise programs to help you avoid hypoglycemia.


Hyperglycemia (High Blood Sugar) and Diabetic Ketoacidosis (DKA)


Hyperglycemia (too much glucose in the blood) may develop if your body has too little insulin. Hyperglycemia can be brought about by any of the following:



  1. Omitting your insulin or taking less than your doctor has prescribed.




  2. Eating significantly more than your meal plan suggests.




  3. Developing a fever, infection, or other significant stressful situation.



In patients with type 1 or insulin–dependent diabetes, prolonged hyperglycemia can result in DKA (a life-threatening emergency). The first symptoms of DKA usually come on gradually, over a period of hours or days, and include a drowsy feeling, flushed face, thirst, loss of appetite, and fruity odor on the breath. With DKA, blood and urine tests show large amounts of glucose and ketones. Heavy breathing and a rapid pulse are more severe symptoms. If uncorrected, prolonged hyperglycemia or DKA can lead to nausea, vomiting, stomach pain, dehydration, loss of consciousness, or death. Therefore, it is important that you obtain medical assistance immediately.


Lipodystrophy


Rarely, administration of insulin subcutaneously can result in lipoatrophy (seen as an apparent depression of the skin) or lipohypertrophy (seen as a raised area of the skin). If you notice either of these conditions, talk to your doctor. A change in your injection technique may help alleviate the problem.


Allergy


Local Allergy — Patients occasionally experience redness, swelling, and itching at the site of injection. This condition, called local allergy, usually clears up in a few days to a few weeks. In some instances, this condition may be related to factors other than insulin, such as irritants in the skin cleansing agent or poor injection technique. If you have local reactions, talk to your doctor.


Systemic Allergy — Less common, but potentially more serious, is generalized allergy to insulin, which may cause rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse, or sweating. Severe cases of generalized allergy may be life threatening. If you think you are having a generalized allergic reaction to insulin, call your doctor immediately.


ADDITIONAL INFORMATION


Information about diabetes may be obtained from your diabetes educator.


Additional information about diabetes and Humulin can be obtained by calling The Lilly Answers Center at 1-800-LillyRx (1-800-545-5979) or by visiting www.LillyDiabetes.com.


Patient Information revised August 22, 2007


Vials manufactured by


Eli Lilly and Company, Indianapolis, IN 46285, USA or


Lilly France, F-67640 Fegersheim, France


for Eli Lilly and Company, Indianapolis, IN 46285, USA


Copyright © 1992, 2007, Eli Lilly and Company. All rights reserved.


PV 5703 AMP



PACKAGE CARTON – Humulin 50/50 Vial 10 mL 1ct


NDC 0002-9515-01


HI-1510


10 mL


100 units per mL


Humulin® 50/50


50% human insulin isophane suspension


50% human insulin injection (rDNA origin)


Humulin 50/50 is being discontinued. Contact your physician to change to another insulin. For information call 1-800-545-5979


For subcutaneous use only.


U-100


Lilly










HUMULIN   50/50
insulin human  injection, suspension










Product Information
Product TypeHUMAN OTC DRUGNDC Product Code (Source)0002-9515
Route of AdministrationSUBCUTANEOUSDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Insulin human (Insulin human)Insulin human100 [iU]  in 1 mL






















Inactive Ingredients
Ingredient NameStrength
Glycerin16 mg  in 1 mL
Metacresol1.6 mg  in 1 mL
Zinc.025 mg  in 1 mL
Phenol0.65 mg  in 1 mL
Protamine sulfate0.172 mg  in 1 mL
Sodium phosphate, dibasic3.78 mg  in 1 mL
Water 
Hydrochloric acid 
Sodium hydroxide 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
10002-9515-011 VIAL In 1 CARTONcontains a VIAL
110 mL In 1 VIALThis package is contained within the CARTON (0002-9515-01)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02010005/18/1992


Labeler - Eli Lilly and Company (006421325)









Establishment
NameAddressID/FEIOperations
Eli Lilly and Company006421325API MANUFACTURE, MANUFACTURE, ANALYSIS









Establishment
NameAddressID/FEIOperations
Covance Laboratories, Inc.937533768ANALYSIS
Revised: 11/2009Eli Lilly and Company




More Humulin 50/50 resources


  • Humulin 50/50 Side Effects (in more detail)
  • Humulin 50/50 Use in Pregnancy & Breastfeeding
  • Humulin 50/50 Drug Interactions
  • Humulin 50/50 Support Group
  • 0 Reviews for Humulin 50/50 - Add your own review/rating


  • Humulin 50/50 Pens MedFacts Consumer Leaflet (Wolters Kluwer)

  • Humulin 50/50 Concise Consumer Information (Cerner Multum)

  • Novolin 70/30 InnoLets MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Humulin 50/50 with other medications


  • Diabetes, Type 1
  • Diabetes, Type 2
  • Gestational Diabetes